As of September 18, 2026, POLYMED is trading at ₹1726.0. The stock exhibits a mixed technical stance across timeframes. Daily indicators suggest consolidation, with the price below key short-term moving averages like the 20-day EMA (₹1729.47) and 20-day SMA (₹1730.27), while remaining above the 50-day SMA (₹1723.94) and 200-day SMA (₹1585.68). The daily Supertrend is bullish at ₹1680.77. Weekly and monthly timeframes show a bullish Supertrend, indicating a potentially stronger underlying trend, though the monthly price is below its 20-day EMA (₹1797.33) and 20-day SMA (₹1836.28). The stock is currently positioned near the middle of its recent trading range, with the closest support identified at the pivot level of ₹1721.93, approximately 0.24% below the current price. Nearest resistance is observed at ₹1743.77, about 1.03% higher. The stock has experienced a current drawdown of -0.39% and exhibits annualized volatility of 41%.

Poly Medicure Limited held its 31st Annual General Meeting (AGM) on September 5, 2026, conducted via video conferencing. During the AGM, the company's audited standalone and consolidated financial statements for the fiscal year ending March 31, 2026, were adopted. Shareholders approved the declaration of a dividend on equity shares and the re-appointment of directors Rishi Baid and Devendra Raj Mehta. Additionally, the re-appointment of cost auditor M/s. Jai Prakash & Company was confirmed. The company noted that the statutory and secretarial audit reports for the period contained no qualifications. The voting results from the AGM were submitted to the exchange on September 7, 2026. In other news, Poly Medicure Limited's officials were scheduled to meet with Sumitomo Mitsui DS Asset Management on September 8, 2026, for a one-on-one discussion. This meeting was subject to change and was not expected to involve the disclosure of unpublished price-sensitive information.

As of September 18, 2026, Poly Medicure (POLYMED) on the NSE is trading at ₹1726.0. This represents a slight increase from its previous price of ₹1712.7. The available evidence does not indicate any new filings or news developments for the company. The company's continuing context remains its profile as Poly Medicure listed on the NSE.

Poly Medicure Limited held its 31st Annual General Meeting (AGM) on September 5, 2026, where shareholders approved the audited financial statements for the fiscal year ending March 31, 2026. The meeting also saw the declaration of a final dividend of ₹3.50 per equity share, representing 70% of the share's face value of ₹5. Shareholder approval was granted for the re-appointment of directors Rishi Baid and Devendra Raj Mehta, along with the re-appointment of M/s. Jai Prakash & Company as the cost auditor for the fiscal year ending March 31, 2027. The company also confirmed that the statutory and secretarial audit reports for the fiscal year 2025-26 were unqualified. In the lead-up to the AGM, the company had communicated with shareholders regarding the meeting arrangements and dividend payment procedures, emphasizing the need to update PAN, KYC, nomination, and bank details for electronic dividend disbursement. Separately, Poly Medicure Limited has been actively engaging in investor relations, with scheduled one-on-one meetings with various asset management firms, including Sumitomo Mitsui DS Asset Management, Waswas Global, Bandhan AMC, Sparx Capital, Wasatch Global, and Bajaj Alternative Investment Ltd., between August 17 and September 8, 2026. The company has stated that no unpublished price-sensitive information will be shared during these interactions.

Poly Medicure's recent operating performance shows a mixed trend across its reported quarters. Revenue from operations saw an increase from ₹493.66 crore in Q3 FY2025-26 to ₹534.51 crore in Q4 FY2025-26, before slightly declining to ₹525.38 crore in Q1 FY2026-27. Profit Before Tax followed a similar pattern, rising from ₹95.93 crore in Q3 FY2025-26 to ₹83.51 crore in Q4 FY2025-26, and then increasing to ₹115.75 crore in Q1 FY2026-27. The net profit, or Profit Loss For Period, mirrored this, moving from ₹70.81 crore in Q3 FY2025-26 to ₹65.04 crore in Q4 FY2025-26, and then to ₹85.27 crore in Q1 FY2026-27. The company's finance costs remained relatively stable, ranging from ₹5.96 crore to ₹6.50 crore over the same periods. The difference between Profit Before Exceptional Items And Tax and Profit Before Tax was notable in Q3 FY2025-26 (₹102.73 crore vs ₹95.93 crore), suggesting potential exceptional items impacting that quarter's pre-tax profit, though this difference was not present in Q4 FY2025-26 or Q1 FY2026-27. Investors may want to monitor revenue growth consistency and the factors influencing profitability margins.

Poly Medicure's technical indicators suggest a constructive setup across multiple timeframes as of September 18, 2026. The weekly trend shows a bullish Super Trend signal at ₹1351.41, with a positive EMA 20 slope of 45.02 and a rising ADX of 30.64, indicating strengthening upward momentum. Daily indicators also point to bullish conditions, with the Super Trend at ₹1680.77 and a positive SMA 50 slope of 5.82. While the daily EMA 20 slope is currently negative at -8.07, the overall trend across weekly and daily charts suggests potential for upward movement, supported by a positive ADX of 13.99 on the daily chart.

Poly Medicure's technical indicators suggest potential headwinds. The daily trend shows the 20-day Exponential Moving Average (EMA) at ₹1729.47 with a negative slope of -8.07 over 5 periods, and the 20-day Simple Moving Average (SMA) at ₹1730.27 with a steeper negative slope of -12.9 over 5 periods. While the 50-day SMA shows a positive slope of 5.82, the overall daily trend indicators, including the Average Directional Index (ADX) at 13.99, point towards a lack of strong directional momentum. The company has experienced a maximum drawdown of -58% and a current drawdown of -39%, indicating significant past price depreciation. Furthermore, the 1-year return stands at -16%, and the year-to-date (YTD) return is -1%. The monthly trend shows the 20-day EMA at ₹1797.33 and the 20-day SMA at ₹1836.28, both higher than the current price, suggesting a potential resistance level. The nearest identified resistance level is ₹1743.77, approximately 1.03% above the current price of ₹1726.0.